Novo Nordisk A/S (NYSE:NVO) Shares Down 0.3%

Shares of Novo Nordisk A/S (NYSE:NVO) fell 0.3% during trading on Tuesday . The stock traded as low as $117.79 and last traded at $118.68. 920,841 shares were traded during trading, a decline of 79% from the average session volume of 4,303,666 shares. The stock had previously closed at $119.07.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NVO. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, September 16th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, Argus upped their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Trading Down 0.8 %

The stock has a 50-day moving average of $131.69 and a 200 day moving average of $132.87. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The stock has a market cap of $530.16 billion, a PE ratio of 40.92, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The business had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.11 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a $0.5126 dividend. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.83%.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds have recently bought and sold shares of the stock. First PREMIER Bank acquired a new position in shares of Novo Nordisk A/S in the first quarter worth about $25,000. 1620 Investment Advisors Inc. acquired a new stake in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $26,000. Finally, Orion Capital Management LLC purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at approximately $26,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.